{"id": "R44864", "inputs": [{"text": "in 1992 , the prescription drug user fee act ( pdufa , now called pdufa i ) gave the food and drug administration ( fda ) the authority to collect fees from the pharmaceutical industry and to use the revenue to support \"the process for the review of human drug applications. .", "tokens": ["in", "1992", ",", "the", "prescription", "drug", "user", "fee", "act", "(", "pdufa", ",", "now", "called", "pdufa", "i", ")", "gave", "the", "food", "and", "drug", "administration", "(", "fda", ")", "the", "authority", "to", "collect", "fees", "from", "the", "pharmaceutical", "industry", "and", "to", "use", "the", "revenue", "to", "support", "``", "the", "process", "for", "the", "review", "of", "human", "drug", "applications", ".", "."], "sentence_id": 1, "word_count": 54}, {"text": "that authority , which expired in 1997 , has been renewed on five subsequent occasions , by pdufa ii ( 1997 ) , pdufa iii ( 2002 ) , pdufa iv ( 2007 ) , pdufa v ( 2012 ) , and pdufa vi ( 2017 ) .", "tokens": ["that", "authority", ",", "which", "expired", "in", "1997", ",", "has", "been", "renewed", "on", "five", "subsequent", "occasions", ",", "by", "pdufa", "ii", "(", "1997", ")", ",", "pdufa", "iii", "(", "2002", ")", ",", "pdufa", "iv", "(", "2007", ")", ",", "pdufa", "v", "(", "2012", ")", ",", "and", "pdufa", "vi", "(", "2017", ")", "."], "sentence_id": 2, "word_count": 48}, {"text": "the most recent reauthorization was title i of the food and drug administration reauthorization act ( fdara , p.l .", "tokens": ["the", "most", "recent", "reauthorization", "was", "title", "i", "of", "the", "food", "and", "drug", "administration", "reauthorization", "act", "(", "fdara", ",", "p.l", "."], "sentence_id": 3, "word_count": 20}, {"text": "115-52 ) , which extends the user fee program through september 30 , 2022 .", "tokens": ["115-52", ")", ",", "which", "extends", "the", "user", "fee", "program", "through", "september", "30", ",", "2022", "."], "sentence_id": 4, "word_count": 15}, {"text": "for fy2017 , 41% of fda's enacted total program level came from user fees ; however , user fee revenue provided 63% of fda's human drugs program budget .", "tokens": ["for", "fy2017", ",", "41", "%", "of", "fda", "'s", "enacted", "total", "program", "level", "came", "from", "user", "fees", ";", "however", ",", "user", "fee", "revenue", "provided", "63", "%", "of", "fda", "'s", "human", "drugs", "program", "budget", "."], "sentence_id": 5, "word_count": 33}, {"text": "pdufa revenue also contributed to the biologics program and agency - wide headquarters and rent budgets .", "tokens": ["pdufa", "revenue", "also", "contributed", "to", "the", "biologics", "program", "and", "agency", "-", "wide", "headquarters", "and", "rent", "budgets", "."], "sentence_id": 6, "word_count": 17}, {"text": "congress first passed pdufa to supplement the fda budget outside of direct appropriations from congress .", "tokens": ["congress", "first", "passed", "pdufa", "to", "supplement", "the", "fda", "budget", "outside", "of", "direct", "appropriations", "from", "congress", "."], "sentence_id": 7, "word_count": 16}, {"text": "the added funds were intended to enable the agency to increase its staff so it could finish new drug application reviews sooner , allowing both earlier patient access to new drugs and earlier industry earnings on those drugs .", "tokens": ["the", "added", "funds", "were", "intended", "to", "enable", "the", "agency", "to", "increase", "its", "staff", "so", "it", "could", "finish", "new", "drug", "application", "reviews", "sooner", ",", "allowing", "both", "earlier", "patient", "access", "to", "new", "drugs", "and", "earlier", "industry", "earnings", "on", "those", "drugs", "."], "sentence_id": 8, "word_count": 39}, {"text": "pdufa i amended the federal food , drug , and cosmetic act ( ffdca ) to establish the authority and the process for collecting and using industry fees ; it also required fda and industry representatives to agree on the performance goals and procedures that the pdufa revenue would support .", "tokens": ["pdufa", "i", "amended", "the", "federal", "food", ",", "drug", ",", "and", "cosmetic", "act", "(", "ffdca", ")", "to", "establish", "the", "authority", "and", "the", "process", "for", "collecting", "and", "using", "industry", "fees", ";", "it", "also", "required", "fda", "and", "industry", "representatives", "to", "agree", "on", "the", "performance", "goals", "and", "procedures", "that", "the", "pdufa", "revenue", "would", "support", "."], "sentence_id": 9, "word_count": 51}, {"text": "this report describes ( 1 ) the origin of prescription drug user fees , ( 2 ) current law as amended by pdufa vi , ( 3 ) the impact of pdufa on fda application review time and the agency's human drugs program budget , and ( 4 ) pdufa vi reauthorization process .", "tokens": ["this", "report", "describes", "(", "1", ")", "the", "origin", "of", "prescription", "drug", "user", "fees", ",", "(", "2", ")", "current", "law", "as", "amended", "by", "pdufa", "vi", ",", "(", "3", ")", "the", "impact", "of", "pdufa", "on", "fda", "application", "review", "time", "and", "the", "agency", "'s", "human", "drugs", "program", "budget", ",", "and", "(", "4", ")", "pdufa", "vi", "reauthorization", "process", "."], "sentence_id": 10, "word_count": 55}, {"text": "in the late 1980s , the median time for fda to approve a new drug application ( nda ) was 29 months .", "tokens": ["in", "the", "late", "1980s", ",", "the", "median", "time", "for", "fda", "to", "approve", "a", "new", "drug", "application", "(", "nda", ")", "was", "29", "months", "."], "sentence_id": 11, "word_count": 23}, {"text": "industry , consumer groups , and fda agreed that the time from submission of a drug or biologics application to fda's decision was unacceptably long .", "tokens": ["industry", ",", "consumer", "groups", ",", "and", "fda", "agreed", "that", "the", "time", "from", "submission", "of", "a", "drug", "or", "biologics", "application", "to", "fda", "'s", "decision", "was", "unacceptably", "long", "."], "sentence_id": 12, "word_count": 27}, {"text": "patient advocates argued that a drug in review \u2014 and therefore not available for sale \u2014 could be the difference between life and death .", "tokens": ["patient", "advocates", "argued", "that", "a", "drug", "in", "review", "\u2014", "and", "therefore", "not", "available", "for", "sale", "\u2014", "could", "be", "the", "difference", "between", "life", "and", "death", "."], "sentence_id": 13, "word_count": 25}, {"text": "manufacturers argued that prolonged review times affected their ability to recoup the costs of research and development .", "tokens": ["manufacturers", "argued", "that", "prolonged", "review", "times", "affected", "their", "ability", "to", "recoup", "the", "costs", "of", "research", "and", "development", "."], "sentence_id": 14, "word_count": 18}, {"text": "during pdufa i consideration , fda estimated that each one - month delay in a review's completion cost a manufacturer an average of $10 million .", "tokens": ["during", "pdufa", "i", "consideration", ",", "fda", "estimated", "that", "each", "one", "-", "month", "delay", "in", "a", "review", "'s", "completion", "cost", "a", "manufacturer", "an", "average", "of", "$", "10", "million", "."], "sentence_id": 15, "word_count": 28}, {"text": "fda argued that it needed more scientists to review incoming drug applications , as well as backlogged applications , and that it had insufficient appropriations to hire additional scientists to conduct these reviews .", "tokens": ["fda", "argued", "that", "it", "needed", "more", "scientists", "to", "review", "incoming", "drug", "applications", ",", "as", "well", "as", "backlogged", "applications", ",", "and", "that", "it", "had", "insufficient", "appropriations", "to", "hire", "additional", "scientists", "to", "conduct", "these", "reviews", "."], "sentence_id": 16, "word_count": 34}, {"text": "for decades , fda had asked congress for permission to implement user fees .", "tokens": ["for", "decades", ",", "fda", "had", "asked", "congress", "for", "permission", "to", "implement", "user", "fees", "."], "sentence_id": 17, "word_count": 14}, {"text": "the pharmaceutical industry generally opposed them , believing the funds might go into the treasury to reduce federal debt rather than help fund drug reviews .", "tokens": ["the", "pharmaceutical", "industry", "generally", "opposed", "them", ",", "believing", "the", "funds", "might", "go", "into", "the", "treasury", "to", "reduce", "federal", "debt", "rather", "than", "help", "fund", "drug", "reviews", "."], "sentence_id": 18, "word_count": 26}, {"text": "the pharmaceutical industry's opposition to user fees was mitigated , thus clearing a path for the 1992 law , when then fda commissioner david kessler worked out an arrangement that met two industry demands: ( 1 ) performance goals , which would set target completion times for various review processes , and ( 2 ) the promise that these fees would supplement \u2014 rather than replace \u2014 funding that congress appropriated to fda .", "tokens": ["the", "pharmaceutical", "industry", "'s", "opposition", "to", "user", "fees", "was", "mitigated", ",", "thus", "clearing", "a", "path", "for", "the", "1992", "law", ",", "when", "then", "fda", "commissioner", "david", "kessler", "worked", "out", "an", "arrangement", "that", "met", "two", "industry", "demands", ":", "(", "1", ")", "performance", "goals", ",", "which", "would", "set", "target", "completion", "times", "for", "various", "review", "processes", ",", "and", "(", "2", ")", "the", "promise", "that", "these", "fees", "would", "supplement", "\u2014", "rather", "than", "replace", "\u2014", "funding", "that", "congress", "appropriated", "to", "fda", "."], "sentence_id": 19, "word_count": 76}, {"text": "those steps helped persuade industry groups that the fees would reduce review times \u2014 and paved the way for congress to authorize a revenue source that fda had sought for over 20 years .", "tokens": ["those", "steps", "helped", "persuade", "industry", "groups", "that", "the", "fees", "would", "reduce", "review", "times", "\u2014", "and", "paved", "the", "way", "for", "congress", "to", "authorize", "a", "revenue", "source", "that", "fda", "had", "sought", "for", "over", "20", "years", "."], "sentence_id": 20, "word_count": 34}, {"text": "pdufa i \u2014 and the subsequent pdufa ii , pdufa iii , pdufa iv , pdufa v , and pdufa vi \u2014 authorized the collection of prescription drug user fees and the use of that revenue for specified activities .", "tokens": ["pdufa", "i", "\u2014", "and", "the", "subsequent", "pdufa", "ii", ",", "pdufa", "iii", ",", "pdufa", "iv", ",", "pdufa", "v", ",", "and", "pdufa", "vi", "\u2014", "authorized", "the", "collection", "of", "prescription", "drug", "user", "fees", "and", "the", "use", "of", "that", "revenue", "for", "specified", "activities", "."], "sentence_id": 21, "word_count": 40}, {"text": "the pdufa vi package consists of two parts: ( 1 ) the performance goals and procedures agreement between fda and industry , which this report refers to as the commitment letter or the agreement ( summarized in appendix a ) , and ( 2 ) statutory language that reauthorizes the program ( summarized in appendix b ) .", "tokens": ["the", "pdufa", "vi", "package", "consists", "of", "two", "parts", ":", "(", "1", ")", "the", "performance", "goals", "and", "procedures", "agreement", "between", "fda", "and", "industry", ",", "which", "this", "report", "refers", "to", "as", "the", "commitment", "letter", "or", "the", "agreement", "(", "summarized", "in", "appendix", "a", ")", ",", "and", "(", "2", ")", "statutory", "language", "that", "reauthorizes", "the", "program", "(", "summarized", "in", "appendix", "b", ")", "."], "sentence_id": 22, "word_count": 59}, {"text": "the timeline for the development of the agreement and the reauthorization of the program is shown in figure 3 .", "tokens": ["the", "timeline", "for", "the", "development", "of", "the", "agreement", "and", "the", "reauthorization", "of", "the", "program", "is", "shown", "in", "figure", "3", "."], "sentence_id": 23, "word_count": 20}, {"text": "the pdufa vi reauthorization process began with a public meeting held in july 2015 , followed by a 30-day comment period .", "tokens": ["the", "pdufa", "vi", "reauthorization", "process", "began", "with", "a", "public", "meeting", "held", "in", "july", "2015", ",", "followed", "by", "a", "30-day", "comment", "period", "."], "sentence_id": 24, "word_count": 22}, {"text": "from september 2015 through february 2016 , fda held meetings with industry and patient and consumer advocacy groups ; minutes of the meetings are available on the fda website .", "tokens": ["from", "september", "2015", "through", "february", "2016", ",", "fda", "held", "meetings", "with", "industry", "and", "patient", "and", "consumer", "advocacy", "groups", ";", "minutes", "of", "the", "meetings", "are", "available", "on", "the", "fda", "website", "."], "sentence_id": 25, "word_count": 30}, {"text": "on july 15 , 2016 , fda published a notice in the federal register announcing the availability of the proposed pdufa vi commitment letter , as well as a public meeting to discuss the proposed recommendations for the pdufa vi reauthorization .", "tokens": ["on", "july", "15", ",", "2016", ",", "fda", "published", "a", "notice", "in", "the", "federal", "register", "announcing", "the", "availability", "of", "the", "proposed", "pdufa", "vi", "commitment", "letter", ",", "as", "well", "as", "a", "public", "meeting", "to", "discuss", "the", "proposed", "recommendations", "for", "the", "pdufa", "vi", "reauthorization", "."], "sentence_id": 26, "word_count": 42}, {"text": "on april 25 , 2017 , user fee legislation was introduced in the senate ( s. 934 ) that would have reauthorized pdufa and the three other human medical product user fee programs , among other things .", "tokens": ["on", "april", "25", ",", "2017", ",", "user", "fee", "legislation", "was", "introduced", "in", "the", "senate", "(", "s.", "934", ")", "that", "would", "have", "reauthorized", "pdufa", "and", "the", "three", "other", "human", "medical", "product", "user", "fee", "programs", ",", "among", "other", "things", "."], "sentence_id": 27, "word_count": 38}, {"text": "on may 11 , 2017 , the senate health , education , labor , and pensions ( help ) committee ordered the bill to be reported with an amendment in the nature of a substitute .", "tokens": ["on", "may", "11", ",", "2017", ",", "the", "senate", "health", ",", "education", ",", "labor", ",", "and", "pensions", "(", "help", ")", "committee", "ordered", "the", "bill", "to", "be", "reported", "with", "an", "amendment", "in", "the", "nature", "of", "a", "substitute", "."], "sentence_id": 28, "word_count": 36}, {"text": "in the house , a version of the fda reauthorization act ( h.r .", "tokens": ["in", "the", "house", ",", "a", "version", "of", "the", "fda", "reauthorization", "act", "(", "h.r", "."], "sentence_id": 29, "word_count": 14}, {"text": "2430 ) was introduced on may 16 , 2017 , and referred to the house energy and commerce subcommittee on health , which approved it with amendments by voice vote on may 18 , 2017 .", "tokens": ["2430", ")", "was", "introduced", "on", "may", "16", ",", "2017", ",", "and", "referred", "to", "the", "house", "energy", "and", "commerce", "subcommittee", "on", "health", ",", "which", "approved", "it", "with", "amendments", "by", "voice", "vote", "on", "may", "18", ",", "2017", "."], "sentence_id": 30, "word_count": 36}, {"text": "the full committee approved the bill on june 7 , 2017 .", "tokens": ["the", "full", "committee", "approved", "the", "bill", "on", "june", "7", ",", "2017", "."], "sentence_id": 31, "word_count": 12}, {"text": "the house passed h.r .", "tokens": ["the", "house", "passed", "h.r", "."], "sentence_id": 32, "word_count": 5}, {"text": "2430 on july 12 , 2017 , and the senate passed it on august 3 , 2017 .", "tokens": ["2430", "on", "july", "12", ",", "2017", ",", "and", "the", "senate", "passed", "it", "on", "august", "3", ",", "2017", "."], "sentence_id": 33, "word_count": 18}, {"text": "h.r .", "tokens": ["h.r", "."], "sentence_id": 34, "word_count": 2}, {"text": "2430 was signed into law as fdara ( p.l .", "tokens": ["2430", "was", "signed", "into", "law", "as", "fdara", "(", "p.l", "."], "sentence_id": 35, "word_count": 10}, {"text": "115-52 ) on august 18 , 2017 .", "tokens": ["115-52", ")", "on", "august", "18", ",", "2017", "."], "sentence_id": 36, "word_count": 8}, {"text": "title i reauthorizes pdufa , allowing fda to collect fees and use the revenue to support specified activities for the review of prescription brand - name drugs .", "tokens": ["title", "i", "reauthorizes", "pdufa", ",", "allowing", "fda", "to", "collect", "fees", "and", "use", "the", "revenue", "to", "support", "specified", "activities", "for", "the", "review", "of", "prescription", "brand", "-", "name", "drugs", "."], "sentence_id": 37, "word_count": 28}, {"text": "fdara includes eight other titles .", "tokens": ["fdara", "includes", "eight", "other", "titles", "."], "sentence_id": 38, "word_count": 6}, {"text": "a separate crs report describes provisions in those titles , which cover reauthorization of the medical device , generic drug , and biosimilar biological product user fees , as well as provisions concerning pediatric drugs and devices , reauthorizations and improvements related to drugs , inspections and regulatory improvements related to devices , improvements to generic drug access , and a set of miscellaneous provisions .", "tokens": ["a", "separate", "crs", "report", "describes", "provisions", "in", "those", "titles", ",", "which", "cover", "reauthorization", "of", "the", "medical", "device", ",", "generic", "drug", ",", "and", "biosimilar", "biological", "product", "user", "fees", ",", "as", "well", "as", "provisions", "concerning", "pediatric", "drugs", "and", "devices", ",", "reauthorizations", "and", "improvements", "related", "to", "drugs", ",", "inspections", "and", "regulatory", "improvements", "related", "to", "devices", ",", "improvements", "to", "generic", "drug", "access", ",", "and", "a", "set", "of", "miscellaneous", "provisions", "."], "sentence_id": 39, "word_count": 66}, {"text": "appendix a .", "tokens": ["appendix", "a", "."], "sentence_id": 40, "word_count": 3}, {"text": "summary of pdufa vi agreement: performance goals and procedures fy2018-fy2022 appendix b .", "tokens": ["summary", "of", "pdufa", "vi", "agreement", ":", "performance", "goals", "and", "procedures", "fy2018-fy2022", "appendix", "b", "."], "sentence_id": 41, "word_count": 14}, {"text": "provisions in ffdca sections 735 , 736 , and 736b appendix c. abbreviations used in this repor .", "tokens": ["provisions", "in", "ffdca", "sections", "735", ",", "736", ",", "and", "736b", "appendix", "c.", "abbreviations", "used", "in", "this", "repor", "."], "sentence_id": 42, "word_count": 18}], "section_names": ["", "introduction", "origin of prescription drug user fees", "current law", "pdufa impact on review time and fda budget", "pdufa vi package"], "section_lengths": [0, 10, 10, 1, 0, 21]}